Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder

Michael Frost, Genie L Bailey, Nicholas Lintzeris, John Strang, Adrian Dunlop, Edward V Nunes, Jakob Billeskov Jansen, Lars Chemnitz Frey, Bernd Weber, Paul Haber, Sonia Oosman, Sonnie Kim, Fredrik Tiberg, Michael Frost, Genie L Bailey, Nicholas Lintzeris, John Strang, Adrian Dunlop, Edward V Nunes, Jakob Billeskov Jansen, Lars Chemnitz Frey, Bernd Weber, Paul Haber, Sonia Oosman, Sonnie Kim, Fredrik Tiberg

Abstract

Aims: To assess the long-term safety of subcutaneous buprenorphine (CAM2038) weekly and monthly depots.

Design: Phase 3, open-label, observational, multi-centre 48-week trial (ClinicalTrials.gov NCT02672111).

Setting: Twenty-six out-patient sites (United States, United Kingdom, Hungary, Denmark, Sweden, Germany, Australia) between 14 December 2015 and 12 April 2017.

Participants: Two hundred and twenty-eight adults with opioid use disorder; 227 received CAM2038 (37 initiated onto CAM2038 and 190 converted from sublingual buprenorphine).

Interventions: CAM2038 weekly (8, 16, 24 or 32 mg) or monthly (64, 96, 128 or 160 mg) with flexible dosing and individualized titration utilizing multiple CAM2038 weekly and monthly doses.

Measurements: Safety variables, urine toxicology samples and self-reported illicit opioid use were collected at each visit. Participants were administered a patient satisfaction survey at months 6 and 12, completed by 162 of 227 (71.4%) participants.

Findings: The study treatment period was completed by 167 of 227 (73.6%) participants. At least one treatment-emergent adverse event (TEAE) was reported by 143 of 227 (63.0%) participants, of whom 60 of 227 (26.4%) reported as being drug-related. Most of the TEAEs, reported by 128 of 227 (56.4%) of participants, were mild or moderate in intensity. Injection-site reactions were reported by 46 of 227 (20.3%) participants, with most [45 of 46 (97.8%)] reported as mild to moderate. Five participants (2.2%) discontinued the study drug due to a TEAE, two cases (0.9%) of which were injection-site-related. No serious adverse events were attributed to the study drug. Among those remaining in the study, the percentage of opioid-negative urine tests combined with self-reports was 63.0% (17 of 27) in new-to-treatment participants and 82.8% (111 of 134) for those converted from sublingual buprenorphine. Participants reported high levels of satisfaction with CAM2038.

Conclusions: Subcutaneous buprenorphine delivered weekly or monthly (CAM2038) was well tolerated, with a systemic safety profile consistent with the known profile of sublingual buprenorphine. CAM2038 weekly and monthly was associated with high retention rates and low levels of illicit opioid use throughout this study.

Keywords: Buprenorphine; CAM2038; Phase 3 trial; depot; long-term safety; opioid use disorder.

© 2019 Braeburn Inc. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.

Figures

Figure 1
Figure 1
Consolidated Standards of Reporting Trials (CONSORT) diagram. aParticipants who completed the treatment period were those who completed a day 337 visit. BPN = buprenorphine; SL BPN = sublingual buprenorphine
Figure 2
Figure 2
Efficacy measures, including (a) treatment period completion (participants who had day 337 visit); (b) percentage of urine samples and self‐reports negative for illicit opioid use (n = participants who provided a urine sample); (c) scores for withdrawal, based on clinical opioid withdrawal scale scores; and (d) need to use visual analogue scale scores. COWS = clinical opioid withdrawal scale; SL BPN/NX = sublingual buprenorphine/naloxone; VAS = visual analogue scale

References

    1. Hedegaard H., Warner M., Miniño A. M. Drug overdose deaths in the United States, 1999–2015, NCHS data brief, no. 273 Hyattsville, MD, National Center for Health Statistics; 2017. Available at: (accessed 3 October 2017) (Archiver at on 13 May 2019).
    1. Roxburgh A., Hall W. D., Dobbins T., Gisev N., Burns L., Pearson S., et al Trends in heroin and pharmaceutical opioid overdose deaths in Australia. Drug Alcohol Depend 2017; 179: 291–298.
    1. Rudd R. A., Aleshire N., Zibbell J. E., Gladden R. M. Increases in drug and opioid overdose deaths—United States, 2000–2014. Morb Mortal Wkly Rep 2016; 64: 1378–1382.
    1. United Nations Office on Drugs and Crime . World Drug Report 2017 (ISBN: 978–92–1‐148291‐1, eISBN: 978–92–1‐060623‐3, United Nations publication, Sales no. E.17.XI.6). Available at: (Accessed 3 October 2017) (Archived at ).
    1. Macarthur G. J., Minozzi S., Martin N., Vickerman P., Deren S., Bruneau J., et al Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta‐analysis. BMJ 2012; 345: e5945.
    1. Sordo L., Barrio G., Bravo M. J., Indave B. I., Degenhardt L., Wiessing L., et al Mortality risk during and after opioid substitution treatment: systematic review and meta‐analysis of cohort studies. BMJ 2017; 357: j1550.
    1. Soyka M., Trader A., Klotsche J., Haberthur A., Buhringer G., Rehm J., et al Criminal behavior in opioid‐dependent patients before and during maintenance therapy: 6‐year follow‐up of a nationally representative cohort sample. J Forensic Sci 2012; 57: 1524–1530.
    1. Connery H. S. Medication‐assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry 2015; 23: 63–75.
    1. Mattick R. P., Breen C., Kimber J., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; 2: CD002207.
    1. Bailey J. E., Campagna E., Dart R. C. Radars system poison center investigators. The underrecognized toll of prescription opioid abuse on young children. Ann Emerg Med 2009; 53: 419–424.
    1. Toce M. S., Burns M. M., O'Donnell K. A. Clinical effects of unintentional pediatric buprenorphine exposures: experience at a single tertiary care center. Clin Toxicol (Phil) 2017; 55: 12–17.
    1. Lofwall M. R., Walsh S. L. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med 2014; 8: 315–326.
    1. Sigmon S. C. The untapped potential of office‐based buprenorphine treatment. JAMA Psychiat 2015; 72: 395–396.
    1. Olsen Y., Sharfstein J. M. Confronting the stigma of opioid use disorder—and its treatment. JAMA 2014; 311: 1393–1394.
    1. Lofwall M. R., Walsh S. L., Nunes E. V., Bailey G. L., Sigmon S. C., Kampman K. M., et al Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med 2018; 178: 764–773.
    1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 5th edn. Washington, DC: American Psychiatric Association; 2013.
    1. Wesson D. R., Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoact Drugs 2003; 35: 253–259.
    1. Kozlowski L. T., Mann R. E., Wilkinson D. A., Poulos C. X. ‘Cravings’ are ambiguous: ask about urges or desires. Addict Behav 1989; 14: 443–445.
    1. Wright N., D'Agnone O., Krajci P., Littlewood R., Alho H., Reimer J., et al Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real‐world experience. J Public Health (Oxf) 2016; 38: e368–e374.
    1. Indivior Inc. SUBOXONE® (buprenorphne and naloxone) sublingual film for sublingual or buccal use. Full prescribing information. Richmond, VA: Indivior Inc; 2015.
    1. Hser Y. I., Saxon A. J., Huang D., Hasson A., Thomas C., Hillhouse M., et al Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi‐site trial. Addiction 2014; 109: 79–87.
    1. Hoffman K., Peyton M. L., Sumner M. Safety of a rapidly dissolving buprenorphine/naloxone sublingual tablet (BNX‐RDT) for treatment of opioid dependence: a multicenter, open‐label extension study. J Addict Med 2017; 11: 217–223.
    1. Fiellin D. A., Pantalon M. V., Chawarski M. C., Moore B. A., Sullivan L. E., O'Connor P. G., et al Counseling plus buprenorphine‐naloxone maintenance therapy for opioid dependence. N Engl J Med 2006; 355: 365–374.
    1. Gryczynski J., Mitchell S. G., Jaffe J. H., O'Grady K. E., Olsen Y. K., Schwartz R. P. Leaving buprenorphine treatment: patients’ reasons for cessation of care. J Subst Abuse Treat 2014; 46: 356–361.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться